Clinical Practice Session
Dosing Hemodialysis: One Size Does Not Fit All, Including the Garabed Eknoyan, MD, Endowed Lectureship
November 02, 2023 | 02:00 PM - 04:00 PM
Location: Room 113, Pennsylvania Convention Center
Session Description
The most common dose of hemodialysis is thrice weekly with a target spKt/Vurea independent of residual kidney function. This session discusses the data that formed the basis of current adequacy guidelines, consideration of residual kidney function to individualize hemodialysis prescriptions, and the economic impact of adjusting dialysis prescriptions.
ASN gratefully acknowledges Wadi N. Suki, MD, for support of the Garabed Eknoyan, MD, Endowed Lectureship. ASN thanks the ASN Diabetic Kidney Disease Collaborative Task Force for assistance with this session.
Learning Objective(s)
- Summarize the data that led to the development of our current hemodialysis adequacy guidelines
- Describe residual kidney functions that hemodialysis cannot replicate
- Discuss the feasibility of prescribing hemodialysis in an incremental fashion for patients with residual kidney function
- Outline the economic considerations that may impact the individualization of dialysis prescriptions
Learning Pathway(s)
- Dialysis
Moderators
Presentations
- Thrice Weekly Hemodialysis and Kt/Vurea: Carved in Stone? The Garabed Eknoyan, MD, Endowed Lectureship
02:00 PM - 02:30 PM
- Value of Residual Kidney Function: What Hemodialysis Cannot Replicate
02:30 PM - 03:00 PM
- Incremental Hemodialysis in Patients with Residual Kidney Function: Is It Possible?
03:00 PM - 03:30 PM
- Economic Considerations of Individualizing Hemodialysis
03:30 PM - 04:00 PM